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Background: Hormone receptor status in human breast cancer cells is a strong indicator of
the aggressiveness of a tumor. Triple negative breast cancers (TNBC) are aggressive, difficult
to treat, and contribute to high incidences of metastasis by possessing characteristics such as
increased tumor cell migration and a large presence of the transmembrane protein, cluster of
differentiation 44 (CD44) on the cell membrane. Estrogen receptor-positive (ER+) cells are
less aggressive and do not migrate until undergoing an epithelial-mesenchymal transition
(EMT).
Methods: The relationship between EMT and CD44 during metastatic events is assessed by
observing changes in EMT markers, tumor cell detachment, and migration following cyto-
kine treatment on both parental and CD44 knockdown human breast tumor cells.
Results: ER+ T47D and MCF-7 human breast cancer cells treated with OSM demonstrate
increased CD44 expression and CD44 cleavage. Conversely, ER- MDA-MB-231 human
breast cancer cells do not show a change in CD44 expression nor undergo EMT in the
presence of OSM. In ER+ cells, knockdown expression of CD44 by shRNA did not prevent
EMT but did change metastatic processes such as cellular detachment and migration. OSM-
induced migration was decreased in both ER+ and ER- cells with shCD44 cells compared to
control cells, while the promotion of tumor cell detachment by OSM was decreased in ER+
MCF7-shCD44 cells, as compared to control cells. Interestingly, OSM-induced detachment
in ER- MDA-MB-231-shCD44 cells that normally don’t detach at significant rates.
Conclusion: OSM promotes both EMT and tumor cell detachment in ER+ breast cancer
cells. Yet, CD44 knockdown did not affect OSM-induced EMT in these cells, while inde-
pendently decreasing OSM-induced cell detachment. These results suggest that regulation of
CD44 by OSM is important for at least part of the metastatic cascade in ER+ breast cancer.
Keywords: epithelial to mesenchymal transition, Oncostatin M, cluster of differentiation 44,
breast tumor metastasis
Background
The primary cause of mortality in patients with breast cancer is not from the
primary tumor itself but its metastasis.1–4 Continued studies addressing breast
cancer metastasis are important for improved patient survival and to gain a better
understanding of the multitude of events that take place during metastatic disease.
In order for tumor cells to metastasize they must undergo a phenotypic change
known as an epithelial-mesenchymal transition (EMT), which allows for the intra-
vasation of the tumor cell into a nearby blood vessel or lymphatic channel.5–7 Once
Correspondence: Cheryl L Jorcyk
Clinical/Translational Research, Biological
Sciences, Biomolecular Sciences Program,
Boise State University, 1910 University
Drive, SN-227, Boise, ID 83725-1515,
USA
Tel +1 208 426 1040
Email cjorcyk@boisestate.edu
Cancer Management and Research Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Cancer Management and Research 2019:11 7721–7737 7721
DovePress © 2019 Covert et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
the primary breast tumor cells are within the network of
vessels they undergo a homing process to specific organs
within the body,8,9 such as the bones, lung, liver, and
brain.10–18 The tumor microenvironment (TME) plays a
major role in the metastatic cascade,19 and signaling from
cytokines present in the TME lead to tumor cell phenoty-
pic changes necessary for metastasis to occur.20
Inflammatory cytokines of the interleukin-6 (IL-6) family
such as oncostatin M (OSM) have been shown to be
important in driving tumor invasion and metastasis.21
OSM is a pleiotropic, IL-6-family cytokine, which is
important in inflammation exhibited during breast tumor
development.22–24 Tumor cells, as well as monocytes,
macrophages, and neutrophils, secrete OSM.25 OSM acti-
vates the JAK/STAT, MAPK, and PI3K/AKT pathways via
binding its receptors, OSM receptor beta (OSMRβ) or
leukemia inhibitory factor receptor beta (LIFRβ), each
dimerized with a common gp130 subunit.21,26,27 Our pre-
vious data and data from the literature have shown that
OSM inhibits proliferation of breast cancer cells, while
increasing metastatic capacity.28,29 OSM causes EMT,
cell detachment, migration, and an overall increase in
tumor cell aggressiveness. Proteins and events involved
in breast tumor metastasis are directly affected by OSM
signaling, which creates a more aggressive phenotype
through the upregulation of proteins such as CD44.
Cluster of differentiation 44 (CD44) is a transmem-
brane protein involved in cell adhesion and migration
after it undergoes cleavage from proteolytic activity.30
Standard CD44 (CD44s) is roughly 80–85 kDa depending
on post-translational modifications.31–33 CD44 contains a
carboxy-terminal portion known as the cytoplasmic tail
and an amino-terminal portion outside the membrane,
folded together by post-translational glycosylation.34,35
CD44 is a major receptor for binding hyaluronic acid
(HA) in the extracellular matrix,36,37 and it binds HA by
its stem region that is directly above the surface of the
membrane and includes domains derived from alterna-
tively spliced exons.38,39 Alternatively spliced CD44,
such as CD44v6 has been found in multiple cancers
types including gastric and head and neck carcinoma.40,41
Depending on the structure of CD44 with its multiple
combinations of exons, signaling differs based on how it
is recognized by an upstream ligand.42,43 The varying roles
of CD44 raises the complexity while studying the protein.
The protein itself is not a potential therapeutic target from
a global knockdown scale because signaling through
CD44 is crucial to the health and function of many
different cells including T cells,44 while others have
shown a potential role for CD44 during metastatic pro-
cesses such as EMT.
CD44 consists of 20 exons; 1–5 and 16–20 comprise
CD44s, whereas 6–15 provide the exons which are capable
of undergoing alternative splicing.45–47 Variant exons 6–15
are termed v1, v2, v3, etc. through v10, and many CD44
variant (CD44v) isoforms exist.47,48 CD44v6 contains only
variant exon 6 plus the CD44 standard and is associated
with highly aggressive tumors.49 CD44v3-10 contains the
standard exons plus variant exons v3-v10 and is less
common than CD44v6.50 ER+ cells possessing an epithe-
lial phenotype display CD44v8-10 known as CD44E
(CD44 epithelial).51 Regardless of the combination of
exons comprising CD44v, exons from the CD44s remain
present despite alternative splicing.52
As the metastatic process begins, CD44 expression is
upregulated and CD44 protein is cleaved, which correlates
within the same time frame that EMT takes place.53 EMT
and the upregulation of CD44 have been shown to be
involved together in breast tumor metastasis.54–56 The
correlation between EMT and CD44 during metastasis
has been shown as the standard form of CD44 becomes
the dominant form of the CD44 protein while EMT takes
place.57 The direct association and timing of EMT and
cellular detachment has yet to be linked to CD44 expres-
sion. CD44s and CD44v have been shown to be strong
biomarkers commonly found in higher percentages of
more aggressive tumor populations,58 that are assumed to
have previously undergone EMT. Although both CD44
and EMT are implicated in breast tumor progression and
metastasis, establishing a direct connection between the
two has proved to be challenging. A connection between
CD44 and tumor progression exists as high CD44 expres-
sion is considered to be hallmark for breast cancer stem
cells (BCSCs).
Cancer stem cells pose a challenge during treatment as
they are capable of controlled cell proliferation.59 CD44
expression is an important marker for a BCSC identifica-
tion within a diverse population of tumor cells.60 The most
common BCSC population studied in human breast cancer
is CD44+/CD24low/-. Metastasis occurs though EMT, cel-
lular detachment, migration and potentially BCSCs evad-
ing common therapeutic treatment.
In this study, we demonstrate a connection between
OSM-induced metastatic events and CD44 during tumor
cellular detachment and migration. Both EMT and CD44
have been linked to metastasis, but there has been a
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question as to whether they are directly or indirectly asso-
ciated. Here, we provided data showing that OSM induces
EMT and upregulates CD44 expression, but that OSM-
induced EMT is independent of CD44. Conversely, we
show that CD44 plays a very specific role in OSM-induced
detachment and migration, both important events in the
metastatic cascade that follows EMT. Furthermore, CD44
knockdown in aggressive ER- TNBC cells contributed to
the cells behaving as a less aggressive (ER+-like) cell
during detachment. These findings delineate another
important mechanism by how OSM induces breast cancer
metastatic potential.
Materials and methods
Cell culture and cytokine stimulation
MCF7 and T47D ER+ luminal A human breast cancer cells
were obtained directly from the American Type Culture
Collection (Rockville, MD), maintained in RPMI-1640
media supplemented with 10% fetal bovine serum (FBS)
and 100 U/mL each of penicillin and streptomycin. Cells
were maintained at 37 °C, 5% carbon dioxide, and 95%
humidity. All media and supplements were obtained from
Hyclone (Logan, UT). Human oncostatin M (OSM)
(Peprotech, Rocky Hill, NJ) was added at 25 ng/mL.61,62
Immunofluorescence staining and
microscopy
2.5×105 cells were plated onto glass coverslips (Thermo
Fisher Scientific). After 24 hrs, cells were treated with or
without OSM for 3 days. After experimental treatment,
cells were rinsed once with PBS and then fixed in ice-cold
methanol for 20 mins. Cells were rinsed 3 times with PBS
for 10 mins. Cells were blocked in PBSAT (1X PBS/1%
BSA/0.5%Triton X-100) for 30 mins and then incubated in
PBSAT containing the primary antibodies human E-cad-
herin (1:200, same as immunoblotting), α-catenin (1:200;
Abcam, Cambridge, UK), Phalloidin for actin (1:200,
Thermo Fisher Scientific, Waltham, MA) overnight. Cells
were washed 3 times in PBS and incubated with PBSAT
containing goat anti-mouse Alexa Flour 488 (1:1000) and
donkey anti-rabbit Alexa Flour 546 (1:500; Molecular
Probes, Invitrogen, Carlsbad, CA) secondary antibodies
for 2 hrs. Cells were washed 3 times in PBS and mounted
using Prolong Gold DAPI (Molecular Probes). Stains were
visualized and confocal microscopy images were taken
using a Zeiss LSM 510 Meta system combined with the
Zeiss Axiovert Observer Z1 inverted microscope and ZEN
2009 imaging software (Carl Zeiss, Inc., Thornwood, NY).
Real time qPCR
Total RNAwas collected using RNA STAT-60 and isolated
per the manufacture’s protocol (Tel-Test; Friendswood,
TX). cDNA was synthesized according to the manufac-
ture’s protocol (High Capacity cDNA Reverse
Transcription Kit, Applied Biosystems, In/Life
Technologies). A LightCycler 96 (Roche Diagnostic
Corporation, Indianapolis, IN) with program settings of
preincubation 1 cycle, 2 step amplification 45 cycles, and
high resolution melting 1 cycle; steps were set at 95
degrees C for 120 seconds. Primers used are shown in
Table 1. ΔΔCq method was used for analyzation of the
data as described by Livak and Schmittgen.63 Statistical
analysis was performed using GraphPad Prism software
for 1 way ANOVA tests.
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Western blot analysis
For whole cell lysates, 5×104 cells were seeded into 24-well
plates (Thermo Fischer Scientific, Rockford, IL), unless other-
wise stated. At the end of the experiment, plates were rinsed
with ice-cold PBS, then placed on ice with 125 μL of RIPA
buffer (Thermo Fischer Scientific) supplemented with 1:100
dilution of Sigma Protease Inhibitor Cocktail and 1 µL/mL
phenylmethylsulfonyl fluoride (PMSF) (Sigma, St. Louis,
MO) for 15 mins, mixing every 5 mins. Plates were scraped
and the contents transferred to an Eppendorf tube. Tubes were
then centrifuged at 14,000 rpm for 20 mins.
Lysates were run on a 7.5–10% SDS-PAGE gel and
transferred to a nitrocellulose membrane. Immunoblot ana-
lysis was performed using primary antibodies for human
E-cadherin (1:2000), β-actin (1:5,000), α-catenin (1:2,500)
(Cell Signaling Secondary, Danvers, MA), CD44 (1:5000)
(kindly provided by Dr. Liliana Mellor and Dr. Knudson).
Antibodies were HRP-conjugated donkey anti-rabbit
(1:5,000).
Flow cytometry
A FACSCaliburTM flow cytometer (BD Biosciences, San
Jose, CA) was used to observe populations of BCSCs
present within a homogenous population. MCF-7 and
T47D cells were treated with OSM (25 ng/mL) for
72 hrs before performing flow cytometry with antibodies
(BD Biosciences, San Jose, CA) to CD44 (1:5 FACS
buffer), CD24 (1:5 FACS buffer), FITC (1:50 FACS buf-
fer), and PE (1:50 FACS buffer) after blocking cells for
10 mins with 1% BSA. Antibodies bound to their appro-
priate targets for 30 mins on ice in the dark. Following
incubation cells were washed 3x with FACS buffer (10%
FBS, 0.1% sodium azide in PBS). Software analysis was
performed using BD FACSCalibur software: CellQuest
Pro, version 6.0 by BD Biosciences. Statistical analysis
was performed using GraphPad Prism software for 1 way
ANOVA tests.
shRNA transduction
Gene knockdown of CD44 and a non-targeting control was
conducted using shERWOOD shRNA lentiviral constructs
(Transomic Technologies, Huntsville, AL). Viral transduc-
tion of MDA-MB-231 luc and MCF-7 luc cells was per-
formed according to manufacturer’s protocol. Puromycin
was used for initial selection followed by fluorescence
microscopy to isolate transduced cell population. CD44
expression was confirmed by Western blot analysis.
Detachment assay
A Detachment assay was used to compare relative tumor
cell detachment in the presence or absence of recombinant
OSM (25 ng/mL). Cells were plated at 10,000 cells per well
in a 24-well plate and allowed to attach overnight. Once
plated, cells were placed in 1% FBS RPMI media for 4 hrs
without treatment. After a 4 hr incubation, cells were then
treated with or without OSM in 1% media for the allotted
time (1, 3, or 5 days). To assess detached cells, media was
collected and centrifuged. The pellets were resuspended in
equal parts of RPMI media and Trypan Blue. Detached cells
were then counted. Cells stained with Trypan blue were
excluded from the counts. Proliferation was also measured,
by trypsinizing adherent cells, pelleting cells, resuspending
pellets in equal parts of RPMI media and Trypan blue, and
counting. Detachment was measured by comparing the
number of proliferating cells and detached cells in the pre-
sence or absence of OSM, and fold detachment was calcu-
lated. Statistical analysis was performed using GraphPad
Prism software for 1 way ANOVA tests.
Wound healing assay
A wound healing assay was used to measure mobility of
breast cancer cell with or without OSM treatment. MCF-7
luc and MDA-MB-231 luc shCD44 and shNTC control
cells were plated at 200,000 cells per well in a 6-well plate
with 10% FBS RPMI media. Once cells were 80–85%
confluent, a scratch was made with a sterile p1000 micro-
pipette tip. Wells were washed with PBS and then 10%
media was placed on each well with or without OSM
(25 ng/mL). Photomicrographs were taken at 72 hrs. The
area of each scratch was measured using ImageJ and fold-
migration was assessed. Statistical analysis was performed
using GraphPad Prism software for 1 way ANOVA tests.
Chemical inhibitor
A MMP inhibitor (GM6001; Santa Cruz Biotechnology),
was added to the cell growth media (10 nM) 2 days before
cytokine treatment in serum-free media; followed by the
addition of complete media and OSM for 2 more days.
Results
OSM induces EMT and CD44+/CD24−/low
BCSC population
The EMT process is commonly studied in vitro using ER+
human breast cells because, compared to ER- cells, they
are less aggressive, phenotypically epithelial, and respond
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to metastatic inducers such as TGF-β and OSM.64,65 Our
studies showed that ER+ MCF7 human breast cancer cells
treated with OSM (25 ng/mL) underwent an EMT over a
3-day period, as displayed by a loss of E-cadherin expres-
sion as measured by immunofluorescence, as well as a
complete dissociation of individual cells breaking away
from the initial colony and subsequently take on a more
spindle-like mesenchymal appearance (Figures 1A and
S1). On the other hand, ER- MDA-MB-231 cells grew
with a mesenchymal phenotype and were not capable of
undergoing an OSM-induced EMT. Previous studies have
shown that developmental transcription factors such as
Slug and Snail are responsible for repressing epithelial
marker proteins, which creates a seesaw effect as cells
progress through EMT.66 ER+ MCF-7 cells treated with
OSM (25 ng/mL) for one hour upregulated both transcrip-
tion factors Slug and Snail by qRT-PCR (Figure 1B). OSM
treatment (25 ng/mL) of MCF-7 cells also resulted in a
slight decrease in expression of the cell-cell adhesion
proteins E-cadherin and α-catenin over time, as measured
by Western blot analysis (Figure 1C). These results
demonstrated that OSM was able to initiate an EMT in
ER+ breast cancer cells by upregulating transcription fac-
tors, down regulating cell-cell adhesion proteins, and pro-
moting a change in cell morphology.
Another common feature associated with tumor pro-
gression and overall metastatic burden is the appearance of
a breast cancer stem cell (BCSC) phenotype, observed as
cells that are CD44+/CD24low within a heterogeneous
tumor cell population. CD44+/CD24low cells have been
shown to possess features of developmental stem cells
with controlled cell division and presence at a defined
location.67 Treatment with OSM (25 ng/mL) for 72 hrs
increased the CD44+/CD24low BCSC population in ER+
MCF-7 cells from 1% to over 1.5% (Figure 1D), and in
T47D cells from 1% to over 4% (Figure 1E). The CD44+/
CD24low BCSC cell population in MCF-7 was not signifi-
cant because of the high basal expression of CD24
observed during FACS analysis. Taken together, OSM
induces both an EMT and the CD44+/CD24low population
of BCSCs in ER+ breast cancer cells, confirming previous
results that OSM is a driver of metastatic potential.
OSM induces both CD44 expression and
cleavage
CD44 expression fluctuates during tumor progression and
metastasis. Our studies showed that OSM induced CD44
expression at the protein level over time in ER+ but not
ER- cells (Figure 2). Treatment of ER+ MCF7 cells with
OSM (25 ng/mL) for 24, 48, and 72 hrs resulted in an
increase in high molecular weight CD44 alternatively
spliced (top panels) isoforms and low molecular weight
cleavage products (lower panels) at each time point
(Figure 2A and B), as measured by Western blot analysis
of whole cell lysates using an antibody specific to the
cytoplasmic fragment of CD44. For ER+ T47D cells,
OSM-induced CD44 high molecular weight CD44 iso-
forms were most prevalent at 48 and 72 hrs (Figure 2C
and D). CD44 expression in the more aggressive ER-
MDA-MB-231 cells showed a high basal level, which
did not change in the presence of OSM during the same
time period (Figure 2E and F). In these experiments, we
observed an OSM-induced increase of high molecular
weight bands larger than the CD44s (70–85 kDa) band.
To support our finding that OSM induced CD44s and
variant CD44 protein expression in ER+ breast cancer
cells, we investigated OSM-induced CD44 mRNA levels
by qRT-PCR. While a non-significant increase in OSM-
induced CD44s expression was observed at 8 hrs in MCF-
7 cells (Figure S2A), OSM did not significantly induce the
mRNA levels of individual CD44 variants (v2 through
v10) at the 8 hr time point, it was observed that OSM
slightly increased CD44 variants (Figure S2B). Together,
these studies suggest that while OSM does not induce
CD44 mRNA expression, it does result in increased levels
of CD44s and variant proteins. These results showed that
in ER+ breast cancer cells, which have a lower basal level
of CD44 expression, OSM increased the expression of
high molecular weight CD44 isoforms, while the more
aggressive TNBC cells that express high basal levels of
CD44, do not respond to OSM.
Proteolytic cleavage of CD44 by matrix metalloprotei-
nases (MMPs) and γ-secretase occurs in close proximity to
the cell membrane and produces low molecular CD44 frag-
ments. Specifically, CD44 is first cleaved by MMP-9 and
subsequently undergoes a second cleavage by γ-secretase
producing a smaller fragment known as the intracellular
domain (ICD) CD44.68 Our lab has previously shown that
OSM induces MMP activity in breast tumor cells.21 T47D
cells treated with the global MMP inhibitor GM6001 for
48 hrs followed by OSM (25 ng/mL) treatment for 48 hrs
decreased the amount of OSM-induced MMP cleavage of
CD44 (Figure S3A and B). Proteolytic activity of MMP
cleavage produces molecular weight bands of 30 kDa and
smaller. Inhibiting OSM-induced MMP activity decreased
Dovepress Covert et al
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Figure 1 OSM induces EMT and a BCSC phenotype in human breast cancer cells (A) MCF-7 luc human breast cancer cells were treated with OSM (25 ng/mL) for 72 hrs.
OSM induces an increased mesenchymal phenotype and a decrease in E-cadherin expression, as measured by immunofluorescence using antibodies for E-cadherin and actin
(63× magnification). (B) MCF-7 cells were treated with OSM (25 ng/mL) for 1 hr, and qPCR was performed with primers for the EMT transcription factors Slug and Snail
(*P<0.05, unpaired t-test). (C) MCF-7 cells were treated with OSM (25 ng/mL) for 24, 48 and 72 hrs, and cell lysates were assessed by Western blot analysis for E-cadherin
and α-catenin (D and E). ER+ MCF-7 and T47D cells were treated with OSM (25 ng/mL) for 72 hrs before flow cytometry was performed. In T47D cells, OSM induces the
CD44+/CD24− BCSC population 3-fold, while a small non-significant increase was seen in MCF-7 cells. **P<0.01, *P<0.05, unpaired t-test.
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the amount of cleaved CD44. To summarize, OSM pro-
motes EMT in ER+ breast cancer cells, increases CD44
expression, and induces proteolytic cleavage of CD44, pre-
sumably through OSM-induced MMP activity.
OSM-induced EMT is independent of
CD44
The relationship between OSM-driven EMT and OSM-
upregulation of CD44 expression was explored by estab-
lishing stable ER+ MCF-7 luc and ER- MDA-MB-231 luc
cells with CD44 expression knockdown using shCD44
lentiviral transduction. MCF-7 luc-shCD44 cells showed
a 70% reduction in CD44s expression by Western blot
analysis compared to control shNTC (non-targeting con-
trol) cells, while MDA-MB-231 luc-shCD44 cells showed
over an 80% reduction in CD44s (Figure 3A and B).
Next, we investigated two transcription factors, Slug
and Snail, which have been shown to drive EMT by
repressing E-cadherin expression that results in loss of
cell-cell adhesion. MCF-7 luc-shCD44 and control
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Figure 2 OSM induces CD44s and CD44 isoforms (above 85 kDa) and cleaved products (below 50 kDa) in ER+ cells, but not ER- cells (A) tumor cells were treated with
OSM for 24, 48, and 72 hrs and whole cell lysates were collected followed by immunoblotting for CD44 using a CD44 antibody kindly provided by Dr. Mellor CD44
expression in MCF-7 (ER+), and (B) quantification of (A). (C) CD44 expression in T47D (ER+), and (D) quantification of (C). (E) CD44 expression in MDA-MB-231 (ER-),
and (F). quantification of (E). All OSM treatment time points were compared to the corresponding non-treatment time points after normalizing to ß-actin. Unpaired t-tests
were performed for each time point. **P<0.01, *P<0.05.
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Figure 3 Reduced CD44 expression does not abrogate OSM-induced EMT in ER+ cells (A) Both MCF-7 luc-shCD44 and MDA-MB-231 luc-shCD44 cells show knockdown
of CD44 protein expression compared to non-targeting control (shNTC) cells by Western blot analysis, and quantification in (B). MCF7 luc-shNTC and shCD44 cells were
treated with OSM (25 ng/mL) for one hour, and qPCR analysis for Slug and Snail was performed. Knockdown of CD44 expression did not decrease OSM-induced Slug (C),
or Snail (D) in these cells (n.s. = no significance, *p<0.05, **P<0.005, ***P<0.001, One way Anova). (E) MCF7 luc-shNTC and shCD44 cells were treated with OSM (25 ng/
mL) for 72 hrs, and E-cadherin was observed via immunofluorescence (20x magnification, scale bar-20 nm). (F) MCF7 luc-shNTC and shCD44 cells were treated with OSM
(25 ng/mL) for 72 hrs to observe EMT morphology by phase contrast images (20x magnification, scale bar-100 µm).
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and qRT-PCR was performed. As expected, OSM
increased both Slug and Snail over 1.5-fold compared to
no treatments in control MCF-7 luc-shNTC cells
(Figure 3C and D). However, OSM treatment of MCF-7
luc-shCD44 cells resulted in no significant change in Slug
expression compared to control shNTC cells, suggesting
that CD44 is not involved in the upregulation of Slug by
OSM (Figure 3C). Interestingly, CD44 knockdown
resulted in a significant increase in OSM-induced Snail
expression compared to control shNTC to cells, suggesting
that the absence of CD44 increased OSM-induced Snail
(Figure 3D).
OSM-repressed E-cadherin expression during EMTwas
observed by confocal microscopy immunostaining in MCF-
7 luc-shCD44 and shNTC cells (Figure 3E). In the presence
of OSM (25 ng/mL) for 72 hrs, shNTC and shCD44 cells
both showed a reduction in the cell-cell adhesion protein, E-
cadherin (Figure 3E). Photomicrographs of MCF-7 luc-
shCD44 and shNTC cells treated with OSM for 72 hrs
were also taken to observe the phenotypic EMT process
(Figure 3F). Although both cell lines underwent character-
istic EMT processes, the MCF-7 shCD44 cells appeared to
form much tighter colonies prior to OSM treatment.
Together, these results suggest that OSM-induced EMT
takes place independently of CD44 in ER+MCF-7 luc cells.
OSM-induced tumor cell detachment is
dependent on CD44
As part of the metastatic cascade, tumor cells must detach
from their established three-dimensional location. We have
previously shown OSM to be a strong inducer of tumor
cell detachment, especially in ER+ breast cancer cells.21
MCF-7 luc-shCD44 and MDA-MB-231 luc-shCD44 cells
were treated with OSM (25 ng/mL), and fold-detachment
was measured over a 5-day period (Figure 4). OSM
induced a 1.8- to 3-fold increase in cell detachment using
the less aggressive ER+ MCF-7 luc-shNTC cells com-
pared to untreated cells (Figure 4A; left). When MCF-7
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Figure 4 Reduced CD44 expression decreases OSM-induced tumor cell detachment in ER+ cells (A) ER+ MCF7 luc-shNTC and shCD44 cells were treated with OSM
(25 ng/mL) over a 5-day period, detached cells were counted on days 1, 3, and 5, and data is represented as fold-change in graphical representation (*P<0.05, **P<0.005,
***P<0.001, one-way Anova). (B) ER- MDA-MB-231 luc-shNTC and shCD44 cells were treated with OSM (25 ng/mL) over a 5-day period, detached cells were counted on
days 1, 3, and 5, and data is represented as fold change calculated by comparing non-OSM treated cells to OSM treated cells and differences between OSM treated shNTC
and shCD44 as shown in graphical representation. ***P<0.001, one-way Anova.
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increase in tumor cell detachment was measured at days 1
and 3 (Figure 4A; right), suggesting that knockdown of
CD44 eliminated or delayed the ability of OSM to induce
ER+ MCF-7 breast tumor cell detachment. The more
aggressive ER- MDA-MB-231 luc-shNTC control cells
did not detach in the presence or absence of OSM
(Figure 4B; left). Interestingly, MDA-MB-231 luc-
shCD44 cells treated with OSM for 5 days showed a 6-
fold increase in tumor cell detachment compared to control
cells, thus mimicking MCF-7 luc shNTC cells (Figure 4B;
right). Therefore, it appears that MDA-MB-231 luc-
shCD44 cells reverted from aggressive and basically
OSM-unresponsive cells to less aggressive cells that
responded to OSM when CD44 expression was reduced.
Together, these results suggest that OSM-induced ER+
MCF-7 tumor cell detachment is dependent on CD44
expression.
OSM-induced tumor cell migration is
dependent on CD44
Following EMT, a tumor cell must utilize two-dimensional
movement in order to initiate invasion and metastasis.
Wound healing assays were performed using ER+ MCF-7
luc-shCD44 and MDA-MB-231 luc-shCD44 cells to quanti-
tate tumor cell migration. MCF-7 luc shNTC cells treated
with OSM (25 ng/mL) for 3 days demonstrated a slight 1.5-
fold increase in migration compared to untreated cells
(Figure 5A), Importantly, MCF-7 luc-shCD44 cells migrated
to a significantly less extent when compared to shNTC con-
trol cells in the presence of OSM (Figure 5A, black bars).
When treated with OSM for 3 days, the ER- MDA-MB-231
luc-shCD44 cells showed a nearly 2.5-fold reduction in the
number of migrating cells compared to MDA-MB-231 luc-
shNTC cells (Figure 5B, black bars). This striking difference
reiterates the importance of CD44 in tumor cell migration for
aggressive ER- breast cancer cells, while demonstrating a
role for OSM-induced CD44 in ER+ MCF-7 cell migration.
In conclusion, OSM-induced CD44 appears to be important
in tumor cell detachment and migration, both necessary for
tumor cells undergoing metastasis.
Discussion
Breast cancer metastasis requires that individual tumor
cells undergo multiple changes and survive in diverse
environments before reaching a secondary location and
expanding. It is speculated that the metastatic cascade
consists of a number of specifically ordered and timed
events that must take place, starting with EMT and
ending in mesenchymal-epithelial transition (MET) and
clonal expansion of each metastasis. CD44 has been
previously shown to be an important driver of invasion
and the metastatic process. In this research, we show
that OSM induces an EMT that is not dependent on
CD44. Rather, OSM-induced CD44 is necessary for
breast tumor cell detachment and migration regulated
by OSM.
Our results presented here compare to previously
published data on OSM-induced EMT by showing a
decrease in epithelial markers and a phenotypic change
to cells in culture.69 We also demonstrated the ability
of OSM to increase a BCSC phenotype, which has
been previously published.70 OSM-induced breast
tumor cell detachment has also been published.71 In
this study, we show for the first time that OSM induces
alternatively spliced and cleaved CD44 protein
expression.
Figure 5 Reduced CD44 expression decreases OSM-induced tumor cell migration
in ER- cells greater than ER+ cells (A) ER+ MCF-7 luc-shNTC and shCD44 cells
were treated with OSM (25 ng/mL) for 3 days, wound healing was analyzed using
ImageJ software, and data was interpreted as fold-change. (B) ER- MDA-MB-231
luc-shNTC and shCD44 cells were treated with OSM (25 ng/mL) for 3 days, wound
healing was analyzed using Image J software, and data was interpreted as fold-
change. ***P<0.001, one-way Anova.
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Other cytokines have been shown to increase meta-
static characteristics in breast cancer, and here we showed
that OSM increased CD44 expression, but did not affect its
alternative splicing. Previous studies have shown cyto-
kines such as TGF-β are strong inducers of CD44.72,73
Our results show OSM induces CD44 expression in a
similar manner to that of TGF-β by increasing CD44
expression and subsequent CD44 cleavage. Although ER-
cells did not respond to OSM in the same manner of ER+,
PR+, HER2- luminal A cells, it was shown CD44 is
actually expressed at such a high basal level that an
increase was not observed and therefore TNBC MDA-
MB-231 luc cells were not used to study induction of
CD44 via OSM, as other publications have shown the
same using this ER- cell line.74 Furthermore, OSM-
induced MMP-9 CD44 cleavage was reduced by using
the non-specific MMP inhibitor GM6001 as shown by
the reduction of low molecular weight bands. Our lab
and others have previously shown that OSM induces the
expression of a family of MMPs.75,76 Our lab was not able
to show that OSM was capable of inducing secretase,
suggesting that OSM’s ability to cleave CD44 is limited
to MMP activity.
The connection between OSM-induced EMT and
CD44 expression was examined using MCF-7 luc and
MDA-MB-231 luc shCD44 cell lines with knockdown
expression of CD44. Non-targeting control (shNTC) cell
lines responded similarly to parental MCF-7 cells in terms
of OSM-induced EMT, transcriptional activity, and EMT-
related proteins. In CD44 knockdown cell lines, EMT
occurred following OSM treatment, but the knockdown
of CD44 in MCF-7 luc cells displayed less detachment
compared to control cell lines. MDA-MB-231 luc shCD44
cells detached at a much larger number compared to con-
trol. Migration was reduced in both MCF-7 luc and MDA-
MB-231 luc shCD44 cells compared to control shNTC
cells suggesting CD44 contributes to migration during
metastasis. Furthermore, with reduced CD44 expression,
MCF7 luc cells grew and responded much differently
compared to the control cells in terms of morphological
changes as they appeared to contain an increased number
of rounded up cell populations and they also took much
longer to adhere to cell culture flasks. These findings
suggest the potential role for CD44 as an adhesion mole-
cule and cell-cell attachment protein. MCF-7 luc-shCD44
cells also grew in much tighter colonies, with small groups
broken away from the primary colony following 72 hrs of
OSM treatment. Cells that broke away from the primary
colony following OSM treatment did not undergo an EMT
as they appeared to be display tighter cell-cell adhesion.
All of this indicates that CD44 was not directly responsi-
ble for an early event in metastasis, EMT. Although pre-
vious studies have displayed a correlation between an
increase in CD44 expression and EMT,77 here we show
they are ordered events as CD44 participates in later
metastatic events, but not in the initial EMT.
Metastatic events such as cellular detachment and
migration have often thought to be steps necessary in the
early to middle stages of metastasis. In the presence of
OSM, control cells migrated more than shCD44 cells and a
similar trend was observed for detachment. Aggressive
cells like the MDA-MB-231 luc cells do not detach in
the presence of OSM, but the knockdown of CD44 pro-
moted OSM-induced detachment. The opposite was shown
in the less aggressive MCF-7 luc cells where OSM-
induced detachment was reduced in the shCD44 group
suggesting CD44 is used by less aggressive cells to
become more metastatic. Others have shown cytokines
such as TGF-β increase detachment and migrationbut our
data shows both events can occur through OSM signaling
and the expression of CD44.
Together our studies show the binding of OSM to its
receptor leads to the promotion of EMT, migration, and
detachment in less aggressive ER+ breast tumor cells
(Figure 6). OSM signaling also leads to an increase in
the upregulation of CD44 expression and CD44 cleavage
in these cells. OSM-induced CD44 cleavage via MMP
Figure 6 OSM signaling induces an EMT and upregulates CD44 and cleavage of
CD44 in breast tumor cells: Once bound to its receptor, OSM induces cells to
undergo EMT and subsequent detachment and migration. OSM signaling increases
expression of the transmembrane protein CD44 and also cleavage via MMPs. OSM-
induced CD44 is involved in migration and detachment as well as docking, which is
the step immediately before extravasation during the metastatic cascade.
Dovepress Covert et al






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
proteolytic action promotes migration and detachment in
less aggressive cells thus making them more aggressive.
CD44 knockdown expression in highly aggressive MDA-
MB-231 luc cells allows for the cells to become receptive
to OSM and adapt to ER+ cell-like sequence of metastatic
events.
Conclusion
The results presented in this manuscript demonstrate that
the inflammatory cytokine OSM promotes CD44 expres-
sion in ER+ breast cancer cells. Furthermore, this CD44
seems to play a central role in OSM-induced tumor cell
detachment but not in EMT. Together, our results suggest
that the regulation of CD44 by OSM is important for at
least part of the metastatic cascade in ER+ breast cancer.
These findings should provide useful in future studies of
human metastatic breast cancer with the goal of develop-
ing potential therapeutics to reduce mortality rates.
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Supplementary materials
Figure S1 OSM induces an EMT in MCF-7 cells. MCF-7 breast tumor cells were treated with OSM (25 ng/mL) for 72 hrs. OSM induces an increased mesenchymal
phenotype, a redistribution in E-cadherin expression (green, upper panels scale bar-20 nm), and a slight decrease in α-catenin expression (green, lower panels scale bar-
20 nm), as measured by immunofluorescence (DAPI = blue).
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Figure S2 OSM has no effect on different CD44 variant mRNA levels in breast cancer cells (A) MCF-7 cells were treated with OSM (25 ng/mL) for 0.5, 1, 4, and 8 hrs
followed by RNA collection and qPCR analysis for CD44s (n=3). (B) MCF-7 cells were treated with OSM (25 ng/mL) for 8 hrs followed by RNA collection and qPCR analysis
for different CD44 splice variants. (n=3).
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Figure S3 OSM-induced CD44 cleavage is reduced by a general MMP inhibitor in ER+ breast tumor cells (A) T47D cells were treated with 10 nM of GM6001 (global MMP
inhibitor) for 48 hrs prior to the addition of OSM (25 ng/mL) for an additional 48 hrs. Whole cell lysates were collected and CD44 Western blot analysis was performed to
observe cleaved products. OSM induces CD44 in T47D cells after 48 hrs; inhibition of MMP activity reduces OSM-induced CD44 cleavage. (B) Quantitation of the 15–
35 kDa bands by ImageJ demonstrate that GM6001 significantly reduces OSM-induced CD44 cleaved products (n=3) (*P<0.05, unpaired t-test). Fold change was calculated
using non-OSM treatment as a baseline control compared to OSM treatment. GM6001 with OSM fold change was calculated by comparing it to OSM treatment in the
absence of GM6001.
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